Patients with diabetes are 10 times more likely to experience lower limb amputations than the general population and amputations have very significant morbidity, mortality, and financial implications. While common risk factors for amputation in patients with diabetes include poor glycemic control, diabetic peripheral neuropathy, or peripheral arterial disease, canagliflozin use was implicated in the CANVAS and CANVAS-R trials. However, the CANVAS Program trials were not specifically designed to evaluate the risk of lower-extremity amputations. Clearly, we need more information about the magnitude of risk when canagliflozin is used widely in a general population and who is at most risk.
Guest Authors: Julie Dally, PharmD, BCPS, BCACP and Amanda Schartel, PharmD, BCACP
Music by Good Talk
The Generic Levothyroxine Conundrum
Is Icosapent Ethyl a QALY-ty Investment?
Level Up! An Abstinence Game for Smoking Cessation
Breaking the SABA-only Rescue Habit: Two Drugs Are Better Than One
Are You Sure? Tolerance of Uncertainty and the Risk of Stress-Related Harm
Top Ten Things Every Clinician Should Know About the 2022 Heart Failure Guidelines
SAGE Wisdom: Analysis of a Self-Administered Gerocognitive Test
Educating Patients and Prescribers About Deprescribing to Reduce Medication Burden May Not Be Enough
Treating mild hypertension during pregnancy: Time for a new CHAPter!
Finally! Something FDA-Approvable for Non-alcoholic Steatohepatitis (NASH)?
Managing Pain in Patients with High Blood Pressure: Is There No Safe PATH?
Continuous Glucose Monitors (CGMs) - Patient Management Strategies and Getting Paid!
A Healthier Way to Commute? Cycling Reduces Mortality in Patients with Diabetes
Annual Wellness Visits: Pharmacists Closing Care Gaps
FOMO — Keeping Up With the Primary Literature
Could a DOAC Replace Warfarin to Treat the Thrombotic Antiphospholipid Syndrome?
The Top Ten Things Every Clinician Should Know About Sacubitril/Valsartan
Don’t Miss a Beat: The Importance of Influenza Vaccination in Patients with Coronary Disease
Why is Thor’s Hammer, Molnupiravir, Considered a 4th Line Option for COVID-19?
Top Ten Things Every Clinician Should Know about the 2022 Medical Standard of Care for Diabetes
Create your
podcast in
minutes
It is Free
Good Mood Revolution
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
Precision Medicine Forum Podcast
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive